Should Incretin Agonist-Based Drugs be Considered for First Line Antihypertensive Therapy?
Dominik Kylies, Leonie Dreher, Ulrich O Wenzel · 2026
Read Should Incretin Agonist-Based Drugs be Considered for First Line Antihypertensive Therapy? by Dominik Kylies, Leonie Dreher, Ulrich O Wenzel (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13149630.txt.
Description
Kylies, Dreher, and Wenzel ask if gut-call drugs should lead blood push care in this twenty twenty-six review. The drugs melt weight and guard the heart past their first use. Their push drops may spring from more than weight loss lone.
Inside, big trials show push falls cross wide folk bands on the drugs. Weight loss bears a fat share of those falls in split math. Direct acts on veins, kidney salt, and nerve calls add their part. No trial yet puts push as its first end mark in the field. The team backs the drugs for high-risk picks, not first-line yet.
Catalog record
| CREATOR | Dominik Kylies, Leonie Dreher, Ulrich O Wenzel |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |